Who is the manufacturer of Larotinib/Larotinib?

Larotrectinib was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. The drug was jointly developed by Loxo (now part of Eli Lilly and Company) and Bayer AG (Germany's Bayer AG). In 2018, the U.S. Food and Drug Administration (FDA) approved larotrectinib to treat cancer patients with certain genetic markers.

Larotrectinib is a selective inhibitor of neurotrophin receptor kinase (NTRK) used to treat certain tumors caused by abnormal "NTRK" genes. Larotrectinib is used when the cancer has spread to other parts of the body or cannot be removed with surgery or other cancer treatments. Larotrectinib is sometimes used after other cancer treatments have failed or stopped working. One type of genetic mutation produces tumors caused by fusions of enzymes in the tropomyosin kinase (TRK) family. Larotrectinib inhibits TRK fusions and shrinks tumors arising from multiple types of cancer.

In clinical studies, some people responded to larotrectinib, but further study is needed. Clinical studies have shown that larotrectinib performs well in combating a variety of solid tumors, with an overall effectiveness rate of up to 75%. The efficacy is long-lasting, with 73% of patients continuing to benefit for at least six months, and 39% of patients benefiting for one year or more. This drug has shown therapeutic efficacy in a variety of NTRK fusion tumors, including soft tissue sarcoma, salivary gland cancer, infantile fibrosarcoma, thyroid cancer, and lung cancer. Thanks to its outstanding clinical performance, larotrectinib received accelerated approval, allowing the FDA to quickly approve this drug for serious diseases based on clinical trial data that predicts patient clinical benefit.